Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
Quanta Therapeutics received FDA IND clearance for QTX3544, an oral G12V-preferring multi-KRAS inhibitor, marking their third IND clearance within a year.
Quanta Therapeutics received FDA IND clearance for QTX3034, a G12D-preferring multi-KRAS inhibitor, paving the way for Phase 1 trials in Q1 2024.